OCMA Member Spotlight October 19, 2018 OCMA Specialty Spotlight OCMA Member Spotlight 0 Edward S. Kim, M.D., M.B.A. As physician-in-chief of City of Hope Orange County and senior vice president and vice physician-in-chief at City of Hope, preeminent oncologist Edward S. Kim, M.D., M.B.A., is leading efforts to fulfill City of Hope’s promise of enhancing access to cancer breakthroughs in Orange County and become a model for the nation in revolutionizing the delivery of cancer treatment and research. Dr. Kim, named a U.S. News and World Report “Top Doctor,” leads City of Hope Orange County’s esteemed team of clinician-scientists with unique cancer expertise. As City of Hope Orange County’s chief physician, he is responsible for driving innovation in cancer care and delivery for the Orange County network of care and the planned Irvine campus. Specifically, he is encouraging and developing new paradigms for translating state-of-the-art research into practice within the community – including introducing new therapies – as well as championing and advocating for cancer patients and their families. Dr. Kim brings a distinguished history of pioneering cancer research and leadership positions at the Levine Cancer Institute in North Carolina and University of Texas MD Anderson Cancer Center. He is among the country’s foremost experts in molecular prognostication for lung, head and neck cancers, which greatly advances cancer detection and personalized therapies. As part of his lifelong commitment to ongoing oncology research, Dr. Kim is also the principal and co-principal investigator on numerous studies and protocols and the author or co-author of more than 200 published original articles, book chapters and reviews in top-tier journals, such as The Lancet, The Lancet Oncology, the Journal of Clinical Oncology, Cancer Discovery, Cancer, Nature Medicine, and Cancer Prevention Research. Before joining City of Hope, Dr. Kim was the chair of Solid Tumor Oncology and Investigational Therapeutics, the Donald S. Kim Distinguished Chair for Cancer Research, and medical director of the Clinical Trials Office at the Levine Cancer Institute, Atrium Health in Charlotte, North Carolina, and a professor of medicine at the University of North Carolina, Chapel Hill. Prior to the Levine Cancer Institute, he held many leadership positions including associate professor (tenured) in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center. Additionally, Dr. Kim has recently completed his Masters in Business Administration at the University of North Carolina Kenan-Flagler School of Business. “My appointment to City of Hope Orange County is the culmination of my career thus far. The vision of City of Hope to redefine the accessibility of cancer treatments is well-aligned with my personal commitment to continually meet unmet needs,” said Dr. Kim. “Along with my prestigious colleagues, we will be creating opportunities for strategic and team-oriented translational research that is delivered through a comprehensive network of care spanning the breadth of the Orange County region.” City of Hope is answering Orange County’s unmet needs by expanding access to advanced therapies not previously available in the region. Presently, nearly 20% of Orange County residents diagnosed with cancer leave the area for highly specialized cancer care, often commuting up to two hours each way to City of Hope’s main Duarte campus. City of Hope launched a Newport Beach, California, location in January as the initial phase of its plans to invest $1 billion, fueled in part by philanthropy, to develop and operate a regional cancer care network featuring a world-class cancer campus of the future on 11 acres in Irvine, California. Opening in 2022, Lennar Foundation Cancer Center will offer highly specialized cancer care, phase 1-3 clinical trials, precision medicine, and early detection and prevention programs. Orange County’s only specialty hospital exclusively dedicated to treating and curing cancer is slated to open on the campus in 2025. Comments are closed.